Janux Therapeutics, Inc. (NASDAQ:JANX) CEO Sells $1,404,750.00 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction on Tuesday, December 24th. The shares were sold at an average price of $56.19, for a total value of $1,404,750.00. Following the completion of the transaction, the chief executive officer now owns 217,054 shares in the company, valued at $12,196,264.26. This represents a 10.33 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

David Alan Campbell also recently made the following trade(s):

• On Tuesday, December 3rd, David Alan Campbell sold 15,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $67.00, for a total transaction of $1,005,000.00.
• On Monday, November 25th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $51.60, for a total transaction of $1,290,000.00.
• On Monday, October 28th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $53.54, for a total value of $1,338,500.00.

Janux Therapeutics Stock Performance

Shares of Janux Therapeutics stock traded down $1.07 during trading on Friday, hitting $54.10. 492,668 shares of the company’s stock were exchanged, compared to its average volume of 784,267. The stock has a market capitalization of $2.84 billion, a price-to-earnings ratio of -46.24 and a beta of 3.29. The business has a 50-day simple moving average of $54.43 and a 200-day simple moving average of $47.43. Janux Therapeutics, Inc. has a 52-week low of $7.79 and a 52-week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The firm’s quarterly revenue was down 82.6% on a year-over-year basis. On average, equities analysts anticipate that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Institutional Trading of Janux Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC lifted its holdings in Janux Therapeutics by 40.0% in the third quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock valued at $114,587,000 after acquiring an additional 721,563 shares during the period. Logos Global Management LP lifted its stake in shares of Janux Therapeutics by 400.0% in the 2nd quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock valued at $31,418,000 after purchasing an additional 600,000 shares during the period. Point72 Asset Management L.P. lifted its stake in shares of Janux Therapeutics by 190.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company’s stock valued at $17,985,000 after purchasing an additional 259,445 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Janux Therapeutics by 202.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock worth $10,639,000 after buying an additional 156,675 shares in the last quarter. Finally, Barclays PLC grew its position in Janux Therapeutics by 496.5% during the third quarter. Barclays PLC now owns 174,061 shares of the company’s stock valued at $7,907,000 after buying an additional 144,883 shares during the period. 75.39% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have weighed in on JANX. HC Wainwright raised their price target on Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a research note on Tuesday, December 3rd. Scotiabank upped their price target on shares of Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a research note on Wednesday, December 4th. Leerink Partnrs upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd. Finally, Stifel Nicolaus upped their target price on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. One analyst has rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $89.90.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.